Cardiorentis announced a pharma partnership with Roche to establish the therapeutic efficacy and safety of Ularitide.Ularitide is the Company's investigational drug for acute heart failure (AHF).
Cardiorentis will incorporate Roche's advanced in vitro diagnostic tests into its TRUE-AHF Phase III Study to characterize the pharmacological properties of Ularitide, evaluate its benefit-risk profile and the appropriate clinical application in patients.
The TRUE-AHF Phase III trial was initiated in August 2012.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Roche
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity